Celldex Reports Positive Data on Barzolvolimab Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy CLDX?
Source: Newsfilter
- Clinical Trial Results: Celldex presented positive data on barzolvolimab at the 2026 AAAAI Annual Meeting, showing that 71% of patients achieved complete symptom relief after 52 weeks of treatment, indicating significant efficacy and potential disease-modifying effects.
- Improvement in Quality of Life: Among patients treated for 52 weeks, 83% reported no impact of the disease on their quality of life, and 74% of those with baseline angioedema were free of it post-treatment, highlighting barzolvolimab's substantial effect on enhancing patient quality of life.
- Global Clinical Trial Progress: Celldex has completed enrollment in its global Phase 3 program for CSU, involving 1,939 patients, making it the largest study conducted in antihistamine-refractory CSU, showcasing the company's leadership in this field.
- Therapeutic Outlook: Barzolvolimab's unique mechanism targets mast cells, positioning it as a potential first-in-class treatment for CSU, ColdU, and symptomatic dermographism, signaling a major breakthrough in the treatment of allergic diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLDX
Wall Street analysts forecast CLDX stock price to rise
10 Analyst Rating
9 Buy
0 Hold
1 Sell
Strong Buy
Current: 30.730
Low
24.00
Averages
55.00
High
90.00
Current: 30.730
Low
24.00
Averages
55.00
High
90.00
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celldex's Barzolvolimab Shows Strong Efficacy in Skin Conditions
- Efficacy Consistency: Celldex Therapeutics' Barzolvolimab demonstrates that retreatment yields the same profound efficacy in patients with Cold Urticaria and Symptomatic Dermographism, indicating its potential to transform treatment strategies for chronic skin conditions.
- Clinical Trial Results: In a Phase 2 open-label extension study, patients who experienced symptom recurrence regained high levels of disease control upon retreatment, with complete response rates consistent with first-time treatment, underscoring the drug's sustained effectiveness.
- Good Safety Profile: Barzolvolimab was well tolerated, with a safety profile in line with earlier studies, supporting its application in real-world treatment scenarios, particularly for patients requiring intermittent therapy.
- Global Research Initiative: Celldex is currently conducting a global Phase 3 program, EMBARQ, to further evaluate Barzolvolimab's efficacy in Cold Urticaria and Symptomatic Dermographism, signaling potential market expansion in the future.
See More
Celldex Presents Positive Data on Barzolvolimab for ColdU and SD Treatment
- Clinical Trial Results: Celldex presented positive data at the 2026 AAAAI Annual Meeting, indicating that re-treatment with barzolvolimab led to a complete response in 62% of ColdU patients and 60% of SD patients at Week 20, highlighting the drug's potential in chronic urticaria treatment.
- Retreatment Mechanism: Barzolvolimab, a humanized monoclonal antibody, targets mast cells with a unique mechanism, enabling rapid improvement in urticaria control upon symptom recurrence, reinforcing its position as a best-in-class treatment option for chronic urticaria patients.
- Study Participation: In the main study, 193 patients received barzolvolimab or placebo, with 121 entering the Open Label Extension (OLE), demonstrating that patients retreated entered the OLE faster than those initially treated, further validating its clinical applicability and flexibility.
- Safety and Tolerability: Barzolvolimab re-treatment exhibited good tolerability with a safety profile consistent with prior studies, indicating its feasibility in real-world applications and potentially offering new treatment options for chronic urticaria patients.
See More
Celldex Reports Positive Data on Barzolvolimab Efficacy
- Clinical Trial Results: Celldex presented positive data on barzolvolimab at the 2026 AAAAI Annual Meeting, showing that 71% of patients achieved complete symptom relief after 52 weeks of treatment, indicating significant efficacy and potential disease-modifying effects.
- Improvement in Quality of Life: Among patients treated for 52 weeks, 83% reported no impact of the disease on their quality of life, and 74% of those with baseline angioedema were free of it post-treatment, highlighting barzolvolimab's substantial effect on enhancing patient quality of life.
- Global Clinical Trial Progress: Celldex has completed enrollment in its global Phase 3 program for CSU, involving 1,939 patients, making it the largest study conducted in antihistamine-refractory CSU, showcasing the company's leadership in this field.
- Therapeutic Outlook: Barzolvolimab's unique mechanism targets mast cells, positioning it as a potential first-in-class treatment for CSU, ColdU, and symptomatic dermographism, signaling a major breakthrough in the treatment of allergic diseases.
See More
Celldex Completes Enrollment for Barzolvolimab Trial Ahead of Schedule
- Enrollment Completion: Celldex announced the completion of enrollment for its large-scale Chronic Spontaneous Urticaria (CSU) clinical trial six months ahead of schedule, with 1,939 patients enrolled, highlighting the significant unmet need in this area, with data expected in Q4 2026.
- Regulatory Submission Plans: The company plans to submit an application for barzolvolimab approval to the U.S. FDA in 2027 based on clinical trial data, aiming to establish its efficacy and safety in CSU patients, which could facilitate market entry.
- Positive Market Sentiment: On Stocktwits, retail sentiment around CLDX stock remains in the 'bullish' territory, with users optimistic about the drug's annual sales potential, projecting the company's market capitalization to rise to $25 billion, indicating strong investor confidence in the drug's prospects.
- Analyst Ratings Optimistic: According to Koyfin data, the average price target for CLDX is $53.36, representing a potential upside of about 73% from current trading levels, with 13 out of 16 analysts rating it 'Buy' or higher, reflecting a positive outlook for the stock.
See More
Celldex Q4 Earnings Miss Expectations
- Disappointing Earnings: Celldex reported a Q4 GAAP EPS of -$1.22, missing expectations by $0.20, indicating ongoing challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: The company generated only $0.12M in revenue for Q4, a staggering 89.8% year-over-year drop, falling short of the anticipated $1.34M, reflecting a notable weakness in product sales that could increase future cash flow pressures.
- Decreased Cash Reserves: As of December 31, 2025, Celldex's cash, cash equivalents, and marketable securities totaled $518.6M, down from $583.2M as of September 30, 2025, highlighting challenges in cash management that may impact its R&D and operational capabilities.
- Clinical Trial Progress: Despite the poor financial performance, Celldex has completed enrollments in late-stage trials for its lead asset, potentially paving the way for future product launches, although short-term financial pressures remain.
See More
Celldex Completes Enrollment in Chronic Spontaneous Urticaria Studies Ahead of Schedule
- Rapid Research Progress: Celldex completed enrollment in its global chronic spontaneous urticaria (CSU) registration studies six months ahead of schedule, enrolling 1,939 patients, which reflects strong interest in barzolvolimab, with topline data expected in Q4 2026 to support a planned BLA submission in 2027.
- New Drug Development Outlook: The company is actively accruing patients in its Phase 3 studies for cold urticaria and symptomatic dermographism (EMBARQ-ColdU and -SD), where barzolvolimab has demonstrated clinical benefits in a large randomized controlled trial, further solidifying its leadership in immunology.
- Financial Position Analysis: As of December 31, 2025, Celldex reported cash and cash equivalents of $518.6 million, down from $583.2 million as of September 30, 2025, primarily due to increased operating expenses in the fourth quarter, indicating the company's commitment to accelerating clinical trials.
- Future Prospects: Celldex anticipates multiple important data readouts in 2026, including topline data from CSU and other indications, marking the company's ongoing efforts to drive innovative treatment solutions that could transform the treatment landscape and enhance its competitive position in the market.
See More
Celldex's Barzolvolimab Shows Strong Efficacy in Skin Conditions
- Efficacy Consistency: Celldex Therapeutics' Barzolvolimab demonstrates that retreatment yields the same profound efficacy in patients with Cold Urticaria and Symptomatic Dermographism, indicating its potential to transform treatment strategies for chronic skin conditions.
- Clinical Trial Results: In a Phase 2 open-label extension study, patients who experienced symptom recurrence regained high levels of disease control upon retreatment, with complete response rates consistent with first-time treatment, underscoring the drug's sustained effectiveness.
- Good Safety Profile: Barzolvolimab was well tolerated, with a safety profile in line with earlier studies, supporting its application in real-world treatment scenarios, particularly for patients requiring intermittent therapy.
- Global Research Initiative: Celldex is currently conducting a global Phase 3 program, EMBARQ, to further evaluate Barzolvolimab's efficacy in Cold Urticaria and Symptomatic Dermographism, signaling potential market expansion in the future.
See More
Celldex Presents Positive Data on Barzolvolimab for ColdU and SD Treatment
- Clinical Trial Results: Celldex presented positive data at the 2026 AAAAI Annual Meeting, indicating that re-treatment with barzolvolimab led to a complete response in 62% of ColdU patients and 60% of SD patients at Week 20, highlighting the drug's potential in chronic urticaria treatment.
- Retreatment Mechanism: Barzolvolimab, a humanized monoclonal antibody, targets mast cells with a unique mechanism, enabling rapid improvement in urticaria control upon symptom recurrence, reinforcing its position as a best-in-class treatment option for chronic urticaria patients.
- Study Participation: In the main study, 193 patients received barzolvolimab or placebo, with 121 entering the Open Label Extension (OLE), demonstrating that patients retreated entered the OLE faster than those initially treated, further validating its clinical applicability and flexibility.
- Safety and Tolerability: Barzolvolimab re-treatment exhibited good tolerability with a safety profile consistent with prior studies, indicating its feasibility in real-world applications and potentially offering new treatment options for chronic urticaria patients.
See More
Celldex Reports Positive Data on Barzolvolimab Efficacy
- Clinical Trial Results: Celldex presented positive data on barzolvolimab at the 2026 AAAAI Annual Meeting, showing that 71% of patients achieved complete symptom relief after 52 weeks of treatment, indicating significant efficacy and potential disease-modifying effects.
- Improvement in Quality of Life: Among patients treated for 52 weeks, 83% reported no impact of the disease on their quality of life, and 74% of those with baseline angioedema were free of it post-treatment, highlighting barzolvolimab's substantial effect on enhancing patient quality of life.
- Global Clinical Trial Progress: Celldex has completed enrollment in its global Phase 3 program for CSU, involving 1,939 patients, making it the largest study conducted in antihistamine-refractory CSU, showcasing the company's leadership in this field.
- Therapeutic Outlook: Barzolvolimab's unique mechanism targets mast cells, positioning it as a potential first-in-class treatment for CSU, ColdU, and symptomatic dermographism, signaling a major breakthrough in the treatment of allergic diseases.
See More
Celldex Completes Enrollment for Barzolvolimab Trial Ahead of Schedule
- Enrollment Completion: Celldex announced the completion of enrollment for its large-scale Chronic Spontaneous Urticaria (CSU) clinical trial six months ahead of schedule, with 1,939 patients enrolled, highlighting the significant unmet need in this area, with data expected in Q4 2026.
- Regulatory Submission Plans: The company plans to submit an application for barzolvolimab approval to the U.S. FDA in 2027 based on clinical trial data, aiming to establish its efficacy and safety in CSU patients, which could facilitate market entry.
- Positive Market Sentiment: On Stocktwits, retail sentiment around CLDX stock remains in the 'bullish' territory, with users optimistic about the drug's annual sales potential, projecting the company's market capitalization to rise to $25 billion, indicating strong investor confidence in the drug's prospects.
- Analyst Ratings Optimistic: According to Koyfin data, the average price target for CLDX is $53.36, representing a potential upside of about 73% from current trading levels, with 13 out of 16 analysts rating it 'Buy' or higher, reflecting a positive outlook for the stock.
See More
Celldex Q4 Earnings Miss Expectations
- Disappointing Earnings: Celldex reported a Q4 GAAP EPS of -$1.22, missing expectations by $0.20, indicating ongoing challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: The company generated only $0.12M in revenue for Q4, a staggering 89.8% year-over-year drop, falling short of the anticipated $1.34M, reflecting a notable weakness in product sales that could increase future cash flow pressures.
- Decreased Cash Reserves: As of December 31, 2025, Celldex's cash, cash equivalents, and marketable securities totaled $518.6M, down from $583.2M as of September 30, 2025, highlighting challenges in cash management that may impact its R&D and operational capabilities.
- Clinical Trial Progress: Despite the poor financial performance, Celldex has completed enrollments in late-stage trials for its lead asset, potentially paving the way for future product launches, although short-term financial pressures remain.
See More
Celldex Completes Enrollment in Chronic Spontaneous Urticaria Studies Ahead of Schedule
- Rapid Research Progress: Celldex completed enrollment in its global chronic spontaneous urticaria (CSU) registration studies six months ahead of schedule, enrolling 1,939 patients, which reflects strong interest in barzolvolimab, with topline data expected in Q4 2026 to support a planned BLA submission in 2027.
- New Drug Development Outlook: The company is actively accruing patients in its Phase 3 studies for cold urticaria and symptomatic dermographism (EMBARQ-ColdU and -SD), where barzolvolimab has demonstrated clinical benefits in a large randomized controlled trial, further solidifying its leadership in immunology.
- Financial Position Analysis: As of December 31, 2025, Celldex reported cash and cash equivalents of $518.6 million, down from $583.2 million as of September 30, 2025, primarily due to increased operating expenses in the fourth quarter, indicating the company's commitment to accelerating clinical trials.
- Future Prospects: Celldex anticipates multiple important data readouts in 2026, including topline data from CSU and other indications, marking the company's ongoing efforts to drive innovative treatment solutions that could transform the treatment landscape and enhance its competitive position in the market.
See More
